neo estrone tab 1.25mg tablet
neolab inc - esterified estrogens - tablet - 1.25mg - esterified estrogens 1.25mg - estrogens
premarin tablet 0.625mg
pfizer (malaysia) sdn. bhd. - oestrogens,conjugated -
premarin 0.3 tablet
pfizer (malaysia) sdn. bhd. - oestrogens,conjugated -
activelle
novo nordisk ltd., israel - estradiol as hemihydrate; norethisterone as acetate - film coated tablets - estradiol as hemihydrate 1 mg; norethisterone as acetate 0.5 mg - norethisterone and estrogen - norethisterone and estrogen - hormone replacement therapy (hrt) for oestrogen deficiency symptoms in women more than one year after menopause. prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of , or contraindicated for, other medicinal products approved for the prevention of osteoporosis. the experience treating women older than 65 years is limited.
premarin 0.625 mg prolonged-release tablets
pfizer healthcare ireland - conjugated estrogens - prolonged-release tablet - 0.625 milligram(s) - natural and semisynthetic estrogens, plain; conjugated estrogens
mirena
bayer israel ltd - levonorgestrel - intrauterine device - levonorgestrel 52 mg - levonorgestrel and estrogen - levonorgestrel and estrogen - contraception and idiopathic menorrhagia. protection from endometrial hyperplasia during estrogen replacement therapy.
premia 2.5 continuous
pfizer new zealand limited - conjugated estrogens 0.625mg (15mg as a dessication with lactose, includes 3% overage.); ; medroxyprogesterone acetate 2.6mg (includes 4% overage.); conjugated estrogens 0.625mg (15mg as a dessication with lactose, includes 3% overage.); medroxyprogesterone acetate 2.6mg (includes 4% overage.) - tablet - active: conjugated estrogens 0.625mg (15mg as a dessication with lactose, includes 3% overage.) medroxyprogesterone acetate 2.6mg (includes 4% overage.) excipient: calcium sulfate carnauba wax glyceryl mono-oleate iron oxide red lactose monohydrate macrogol 20000 magnesium stearate methylcellulose microcrystalline cellulose opacode black s-8-27741 povidone shellac stearic acid sucrose titanium dioxide active: conjugated estrogens 0.625mg (15mg as a dessication with lactose, includes 3% overage.) medroxyprogesterone acetate 2.6mg (includes 4% overage.) excipient: calcium sulfate carnauba wax glyceryl mono-oleate iron oxide red lactose monohydrate macrogol 20000 magnesium stearate methylcellulose microcrystalline cellulose opacode black s-8-27741 povidone shellac stearic acid sucrose titanium dioxide
premia 5 continuous
pfizer new zealand limited - conjugated estrogens 0.625mg (15mg as a dessication with lactose. includes 3% overage.); ; medroxyprogesterone acetate 5mg (includes 4% overage); conjugated estrogens 0.625mg (15mg as a dessication with lactose. includes 3% overage.); medroxyprogesterone acetate 5mg (includes 4% overage) - tablet - active: conjugated estrogens 0.625mg (15mg as a dessication with lactose. includes 3% overage.) medroxyprogesterone acetate 5mg (includes 4% overage) excipient: calcium sulfate carnauba wax glyceryl mono-oleate iron oxide red lactose monohydrate macrogols magnesium stearate methylcellulose microcrystalline cellulose opacode black s-8-27741 povidone shellac stearic acid sucrose titanium dioxide active: conjugated estrogens 0.625mg (15mg as a dessication with lactose. includes 3% overage.) medroxyprogesterone acetate 5mg (includes 4% overage) excipient: calcium sulfate carnauba wax glyceryl mono-oleate indigo carmine lactose monohydrate macrogols magnesium stearate methylcellulose microcrystalline cellulose opacode black s-8-27741 povidone shellac stearic acid sucrose titanium dioxide
premarin 0.3 mg prolonged-release tablets
pfizer healthcare ireland - conjugated estrogens - prolonged-release tablet - 0.3 milligram(s) - natural and semisynthetic estrogens, plain; conjugated estrogens
premarin 1.25 mg prolonged-release tablets
pfizer healthcare ireland - conjugated estrogens - prolonged-release tablet - 1.25 milligram(s) - natural and semisynthetic estrogens, plain; conjugated estrogens